Table 17.

Change in body mass index in individual studies

Study	Body mass index (kg/m2)			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	30.0 (3.8)	28.7 (3.5)	0.001	0.124
	Control	29.4 (3.1)	28.8 (2.8)	0.019
Shibuya et al[13]	Luseogliflozin	27.9 (26.2, 28.7)	27.0 (25.6, 28.3)	0.002	0.031
	Metformin	27.2 (24.8, 32.1)	27.3 (24.3, 31.6)	0.646
Ohki et al[15]	Ipragliflozin	30.1 (26.1-31.4)	27.6 (25.3-30.2)	< 0.01	-
Seko et al[16]	SGLT-2 inhibitor	29.6 (0.7)	28.3 (0.7)	< 0.001	-
	Sitagliptin	29.2 (1.5)	28.9 (1.4)	0.295
Sumida et al[18]	Luseogliflozin	27.8 (3.6)	27.2 (1.0)	< 0.001	-

SGLT-2: Sodium glucose cotransporter-2.